Chungen Qian1, Mi Zhou2, Fangming Cheng2, Xiaotao Lin2, Yijun Gong2, Xiaobing Xie3, Ping Li3, Zhiyong Li4, Pingan Zhang5, Zejin Liu6, Fang Hu7, Yun Wang8, Quan Li9, Yan Zhu10, Guikai Duan10, Yinting Xing11, Huanyu Song11, Wenfang Xu12, Bi-Feng Liu1, Fuzhen Xia2. 1. The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics - Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China. 2. Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, YHLO Bioscience Building, Shenzhen, Guangdong, P.R. China. 3. Department of Medical Laboratory and Pathology Center, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, P.R. China. 4. Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, P.R. China. 5. Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, P.R. China. 6. Department of Clinical Laboratory, Wuhan Asia General Hospital, Wuhan, Hubei, P.R. China. 7. Department of Clinical Laboratory, Huangshi Central Hospital, Edong Healthcare Group (Affiliated Hospital of Hubei Polytechnic University), Huangshi, Hubei, P.R. China. 8. Department of Clinical Laboratory, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China. 9. Department of Clinical Laboratory, Changshou People's Hospital, Chongqing, P.R. China. 10. Department of Clinical Laboratory, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen, Guangdong, P.R. China. 11. Department of Clinical Laboratory, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China. 12. Department of Clinical Laboratory, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, P.R. China.
Abstract
Objectives: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally. The laboratory diagnosis of SARS-CoV-2 infection has relied on nucleic acid testing; however, it has some limitations, such as low throughput and high rates of false negatives. Tests of higher sensitivity are needed to effectively identify infected patients. Methods: This study has developed fully automated chemiluminescent immunoassays to determine IgM and IgG antibodies to SARS-CoV-2 in human serum. The assay performance has been evaluated at 10 hospitals. Clinical specificity was evaluated by measuring 972 hospitalized patients and 586 donors of a normal population. Clinical sensitivity was assessed on 513 confirmed cases of SARS-CoV-2 by RT-PCR. Results: The assays demonstrated satisfied assay precision with coefficient of variation of less than 4.45%. Inactivation of specimen did not affect assay measurement. SARS-CoV-2 IgM showed clinical specificity of 97.33 and 99.49% for hospitalized patients and the normal population respectively, and SARS-CoV-2 IgG showed clinical specificity of 97.43 and 99.15% respectively. SARS-CoV-2 IgM showed clinical sensitivity of 82.54, 92.93, and 84.62% before 7 days, 7-14 days, and after 14 days respectively, since onset of symptoms, and SARS-CoV-2 IgG showed clinical sensitivity of 80.95, 97.98, and 99.15% respectively at the same time points above. Conclusions: We have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum. The assays demonstrated high clinical specificity and sensitivity, and add great value to nucleic acid testing in fighting against the global pandemic of the SARS-CoV-2 infection.
Objectives: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally. The laboratory diagnosis of SARS-CoV-2 infection has relied on nucleic acid testing; however, it has some limitations, such as low throughput and high rates of false negatives. Tests of higher sensitivity are needed to effectively identify infectedpatients. Methods: This study has developed fully automated chemiluminescent immunoassays to determine IgM and IgG antibodies to SARS-CoV-2 in human serum. The assay performance has been evaluated at 10 hospitals. Clinical specificity was evaluated by measuring 972 hospitalized patients and 586 donors of a normal population. Clinical sensitivity was assessed on 513 confirmed cases of SARS-CoV-2 by RT-PCR. Results: The assays demonstrated satisfied assay precision with coefficient of variation of less than 4.45%. Inactivation of specimen did not affect assay measurement. SARS-CoV-2 IgM showed clinical specificity of 97.33 and 99.49% for hospitalized patients and the normal population respectively, and SARS-CoV-2 IgG showed clinical specificity of 97.43 and 99.15% respectively. SARS-CoV-2 IgM showed clinical sensitivity of 82.54, 92.93, and 84.62% before 7 days, 7-14 days, and after 14 days respectively, since onset of symptoms, and SARS-CoV-2 IgG showed clinical sensitivity of 80.95, 97.98, and 99.15% respectively at the same time points above. Conclusions: We have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum. The assays demonstrated high clinical specificity and sensitivity, and add great value to nucleic acid testing in fighting against the global pandemic of the SARS-CoV-2 infection.
Authors: Jonathan J Deeks; Jacqueline Dinnes; Yemisi Takwoingi; Clare Davenport; René Spijker; Sian Taylor-Phillips; Ada Adriano; Sophie Beese; Janine Dretzke; Lavinia Ferrante di Ruffano; Isobel M Harris; Malcolm J Price; Sabine Dittrich; Devy Emperador; Lotty Hooft; Mariska Mg Leeflang; Ann Van den Bruel Journal: Cochrane Database Syst Rev Date: 2020-06-25
Authors: Pablo Barreiro; Francisco Javier Candel; Juan Carlos Sanz; Jesús San Román; María Del Mar Carretero; Marta Pérez-Abeledo; Belén Ramos; José Manuel Viñuela-Prieto; Jesús Canora; Francisco Javier Martínez-Peromingo; Antonio Zapatero Journal: Viruses Date: 2021-05-10 Impact factor: 5.048
Authors: Antonio La Marca; Martina Capuzzo; Tiziana Paglia; Laura Roli; Tommaso Trenti; Scott M Nelson Journal: Reprod Biomed Online Date: 2020-06-14 Impact factor: 3.828